Skip to main content
[Preprint]. 2023 Jan 2:2023.01.01.522436. [Version 1] doi: 10.1101/2023.01.01.522436

Fig. 3: Mechanisms underlying RIPTAC differential biology.

Fig. 3:

a) The FKBP ligand accumulates selectively in 293_HFL cells b) Non-covalent RIPTACs also accumulate selectively in 293_HFL cells c&d) RIPTAC activity in 7 day viability assays can be competed off by pre-treatment with 10μM HLDA-001 in the case of non-covalent RIPTACs and 300nM TAMRA-CA in the case of covalent RIPTACs e) RIPTAC HLDA-119 is a 20-fold more potent CDK9 inhibitor in 293_HFL cells than in control 293_GFPL cells.